2-氨基-6-溴喹唑啉 | 190273-89-3

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 2-氨基-6-溴喹唑啉
• 中文别名: 6-溴-2-喹唑啉胺
• 英文名称: 6-bromoquinazolin-2-amine
• CAS: 190273-89-3
• 化学式: C₈H₆BrN₃
• 分子量: 224.06
• InChiKey: IJXKEDDKGGBSBX-UHFFFAOYSA-N

物化性质

• 沸点：
  425.3±37.0 °C(Predicted)
• 密度：
  1.744±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Amino-6-bromoquinazoline
Synonyms: 6-Bromoquinazolin-2-amine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Amino-6-bromoquinazoline
CAS number: 190273-89-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H6BrN3
Molecular weight: 224.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基-6-溴喹唑啉 在 copper(l) iodide 、 二碘甲烷 、 亚硝酸异戊酯 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以43%的产率得到6-溴-2-碘喹唑啉
  参考文献：
  名称：

  新型N-芳基-4- [6-（2-氟吡啶-3-基）喹唑啉-2-基]-哌嗪-1-羧酰胺或-甲硫基酰胺衍生物的合成及其抗菌活性

  摘要：

  通过对5-溴-2-氟苯甲醛进行环化反应，合成了 一系列新颖的N-芳基-4- [6-（2-（氟吡啶-3-基）喹唑啉-2-基]-哌嗪-1-甲酰胺或-甲硫酰胺衍生物。在二甲基乙酰胺的存在下，加入碳酸氢胍和碳酸胍，然后在碘化铜的存在下，用异戊基亚硝酸盐和二碘甲烷处理，得到6-溴-2-碘代喹唑啉。后者在三乙胺存在下用哌嗪处理，然后在Pd（PPh 3）2 Cl 2存在下用（2-氟吡啶-3-基）硼酸处理。得到6-（2-氟吡啶-3-基）-2-（哌嗪-1-基）喹唑啉，将其进一步用各种取代的芳基异氰酸酯和芳基异硫氰酸酯处理以获得标题化合物。通过LC-MS，1 H，13 C NMR，IR以及质谱和元素分析确认了合成化合物的化学结构。评价所有合成的化合物对两种革兰氏阳性和两种革兰氏阴性细菌，以及两种不同的抗生素抗性大肠杆菌菌株的体外抗菌活性，以及对两种真菌菌株的抗真菌活性。一些化合物已显示出潜在的抗菌活性。

  DOI：

  10.1007/s10593-015-1660-2
• 作为产物：
  描述：

  5-溴-2-硝基苯甲醛 在 盐酸 、 铁粉 作用下， 以 乙醚 、 乙醇 、 水 为溶剂， 反应 16.08h， 生成 2-氨基-6-溴喹唑啉
  参考文献：
  名称：

  一种医药中间体N-芳基喹唑啉-2-胺化合物的制备方法

  摘要：

  本发明公开了一种N-芳基喹唑啉-2-胺化合物的制备方法，属于药物合成领域。该方法以3-溴苯甲醛为起始原料，通过硝化、还原、与氰胺的关环、偶联、取代五步得到N-芳基喹唑啉-2-胺化合物。与现有的路线相比，本发明的制备方法原料易得、整个反应路线产率较高、反应条件温和，操作简单、生产成本较低等特点，非常适合工业化生产。

  公开号：

  CN105669566A
• 作为试剂：
  描述：

  2-氨基-6-溴喹唑啉 、 sodium;hydride 、 碘甲烷 在 氮气 、 水 、 二氯甲烷 、 Sodium sulfate-III 、 2-氨基-6-溴喹唑啉 、 ethyl acetate n-hexane 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 以afforded pure 6-bromo-N-methylquinazolin-2-amine (Example 714) as a yellow solid MS m/z=239 [M+H]+的产率得到6-溴-2-(N-甲基氨基)喹唑啉
  参考文献：
  名称：

  Aryl nitrogen-containing bicyclic compounds and methods of use

  摘要：

  本发明涉及一种新的化合物类别，对蛋白激酶介导的疾病，包括炎症、癌症和相关疾病的预防和治疗有用。该化合物具有一般的式子I，其中A1、A2、A3、B、R1、R2、R3和R4在此定义。因此，本发明还涉及包含本发明化合物的制药组合物，使用本发明化合物和组合物预防和治疗激酶介导的疾病的方法，以及用于制备本发明化合物的中间体和过程。

  公开号：

  US20070054916A1

文献信息

• [EN] PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] COMPOSÉS DE PYRIMIDINE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：GENENTECH INC

  公开号：WO2010014939A1

  公开（公告）日：2010-02-04

  Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).

  揭示了公式I的化合物，包括立体异构体、几何异构体、互变异构体、溶剂合物、代谢物和其药学上可接受的盐，这些化合物在调节PIKK相关激酶信号传导方面很有用，例如mTOR，并用于治疗至少部分由PIKK信号传导途径失调引起的疾病（例如癌症）。
• Microwave-Assisted Preparation of Fused Bicyclic Heteroaryl Boronates:  Application in One-Pot Suzuki Couplings
  作者：Erin F. DiMauro、Jason R. Vitullo

  DOI：10.1021/jo060218p

  日期：2006.5.1

  The rapid and efficient synthesis of various disubstituted 5,6-fused heterocycles using a microwave-assisted one-pot cyclization−Suzuki coupling approach is described. This work highlights the tolerance of the boronic ester functional group to a variety of reaction conditions and the utility of functionalized boronates as penultimate intermediates in the synthesis of diverse compound libraries.

  描述了使用微波辅助的一锅环化-Suzuki偶联方法快速有效地合成各种二取代的5,6-稠合杂环的方法。这项工作强调了硼酸酯官能团对各种反应条件的耐受性以及官能化的硼酸盐作为倒数第二种中间体在各种化合物库的合成中的用途。
• [EN] IRE1 SMALL MOLECULE INHIBITORS<br/>[FR] INHIBITEURS DE PETITES MOLÉCULES IRE1
  申请人：QUENTIS THERAPEUTICS INC

  公开号：WO2018102751A1

  公开（公告）日：2018-06-07

  Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.

  本文提供了针对IRE1蛋白家族成员的小分子抑制剂。结合可以是直接的或间接的。此外，本文提供了使用IRE1小分子抑制剂用于治疗或改善受试者癌症的方法。此外，本文描述的IRE1小分子抑制剂用于治疗癌症，其中癌症是实体或血液系统的癌症。
• [EN] IMIDAZOLIDINONE DERIVATIVES AS INHIBITORS OF PERK<br/>[FR] DÉRIVÉS D'IMIDAZOLIDINONE COMME INHIBITEURS DE PERK
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD

  公开号：WO2017046739A1

  公开（公告）日：2017-03-23

  The invention is directed to substituted imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I (I) wherein R1, R2, R3, R4, R5, R6, R7, X, Y1, Y2 and Z are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes, as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Sträussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  这项发明涉及取代咪唑烷酮衍生物。具体而言，该发明涉及根据式I（I）中R1、R2、R3、R4、R5、R6、R7、X、Y1、Y2和Z所定义的化合物。该发明的化合物是PERK的抑制剂，可用于治疗癌症、癌前综合征、阿尔茨海默病、神经病性疼痛、脊髓损伤、创伤性脑损伤、缺血性中风、中风、帕金森病、糖尿病、代谢综合征、代谢紊乱、亨廷顿病、克雅氏病、致命性家族性失眠、格斯特曼-施特劳斯勒-谢因克症候群及相关朊蛋白病、肌萎缩侧索硬化、进行性核上性麻痹、心肌梗死、心血管疾病、炎症、器官纤维化、肝脏慢性和急性疾病、脂肪肝病、肝脂肪变性、肝纤维化、肺部慢性和急性疾病、肺纤维化、肾脏慢性和急性疾病、肾脏纤维化、慢性创伤性脑病（CTE）、神经退行性疾病、痴呆症、额颞叶痴呆症、tau蛋白病、皮克氏病、尼曼-皮克氏病、淀粉样变性、认知障碍、动脉粥样硬化、眼部疾病、心律失常、器官移植以及器官移植用途中的运输。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制PERK活性和治疗相关疾病的方法。
• [EN] IRE1 SMALL MOLECULE INHIBITORS<br/>[FR] PETITES MOLÉCULES INHIBITRICES D'IRE1
  申请人：QUENTIS THERAPEUTICS INC

  公开号：WO2018222918A1

  公开（公告）日：2018-12-06

  Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.

  本文提供了针对IRE1蛋白家族成员的小分子抑制剂。结合可以是直接的或间接的。此外，本文提供了使用IRE1小分子抑制剂用于治疗或改善受试者癌症的方法。此外，本文描述的IRE1小分子抑制剂用于治疗癌症，其中癌症是实体或血液系统的癌症。